Study wrapper · #663
[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders].
Editor's note
This study examined Selank's immune-modulating effects using both patient samples and in-vitro work, focused on the anxiolytic/immunotropic overlap in people with anxiety-asthenic disorders. In vitro, researchers reported that Selank (10^-7 M) fully suppressed IL-6 gene expression in blood cells from patients with depression but not from healthy controls, while also increasing IL-6 protein in patient cell cultures. In vivo, patients with generalized anxiety disorder and neurasthenia given Selank for 14 days showed shifts in Th1/Th2 cytokine balance in serum, with the changes inversely correlated. The authors propose Selank as a novel immunomodulator and adaptogen. For Selank, this is among the more human-relevant items here, bridging its anxiolytic and immune profiles. Weigh it as mixed and preliminary: it combines cell-culture and small clinical observations without a described control arm or randomization, and endpoints are cytokine measures rather than clinical outcomes. Human data are needed before firmer conclusions can be drawn.
Plain-language abstract
This study looked at how Selank affects the immune system in people with anxiety-related and fatigue-type (asthenic) disorders, using both laboratory tests on patients' blood cells and a short course of treatment. In the lab, Selank completely switched off the gene for IL-6 (an immune-signaling molecule) in blood cells from patients with depression, but not in cells from healthy people; in patient cell cultures, it also raised IL-6 protein levels. In patients who took Selank for 14 days, the balance between two arms of the immune response (Th1 and Th2) shifted in their blood, with the two changes moving in opposite directions. The authors suggest Selank could act as an immune modulator and a stress adaptogen, possibly useful for older or stressed people. This combined small patient observations with cell studies and did not describe a comparison group or random assignment, and it measured immune-signaling molecules rather than health outcomes. It is a suggestive but preliminary human-related finding, not proof of a clinical benefit.